In this manuscript, the authors provide a detailed account of the preclinical animal studies that demonstrated efficacy and safety of an oligodendrocyte progenitor cell therapy product currently in clinical testing in the U.S. for patients with cervical spinal cord injury (SCiStar clinical trial). This work not only documents the supporting data that led to initiation of the SCiStar clinical trial, but also because it provides examples of the kinds of preclinical testing that should be considered for future pluripotent stem cell-based therapies that target neurological injury and disease.
In this study, researchers describe two novel complementation assays, with which they demonstrate that pluripotent stem cells (PSC)-derived osteoblasts can compensate for the loss of osteoblast lineage cells in transgenic mice to form mineralized bone and bone marrow hematopoietic niche in vivo. Remarkably, the loss of >50% of endogenous osteoblasts during embryonic skeletal development can be rescued by the injected PSCs. These assays will greatly enhance the ability of researchers to evaluate the contribution of specific osteoblast lineage populations to skeletal development and hematopoiesis.
A new study suggests that CAMKK1 overexpression in mesenchymal stem cells can potentiate cardiac repair via the modulation of secreted paracrine acting factors